NSE
Alembic Pharmaceuticals LimitedAPLLTD
Alembic Pharmaceuticals Limited is an Indian pharmaceutical company known for its generic drugs.
| Key products | Generic drugs, APIs (Active Pharmaceutical Ingredients) |
|---|---|
| Geography | India, USA, Europe |
| Competitors | Dr Reddy's Laboratories, Cipla |
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
Dividend - Rs 11 Per Share
ex 2025-07-29
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | MTNL | +₹41.3 Cr | 331 | — | — | — | — |
| 2 | ATALREAL | +₹7 Cr | 367 | — | — | — | — |
| 3 | GATECH | +₹0.4 Cr | 298 | — | — | — | — |
| 4 | APLLTDThis | — | — | — | — | — | — |
| 5 | IRMENERGY | −₹2.2 Cr | 356 | — | — | — | — |
| 6 | QUADFUTURE | −₹9 Cr | 581 | — | — | — | — |
| 7 | MOBIKWIK | −₹150.9 Cr | 975 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
SWOT
Strengths
- • Diversified portfolio of generic drugs
- • Strong presence in the US market
- • In-house manufacturing capabilities
- • Research and development investments
Weaknesses
- • Dependence on a few key products
- • Competition from established players
- • Regulatory challenges in India
- • High operating costs
Opportunities
- • Growing demand for generic drugs in emerging markets
- • Increasing focus on biosimilars
- • Expansion into new therapeutic areas
- • Partnerships with international companies
Threats
- • Intense competition from generic drug manufacturers
- • Fluctuating raw material prices
- • Regulatory changes in India and globally
- • Economic downturn affecting healthcare spending
AI-generated from our data — verify before relying on it.
- 2026-06-12FilingAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 12, 2026, titledPress Release
- 2026-06-11FilingAlembic Pharmaceuticals Limited has informed the Exchange about Credit RatingRating
- 2026-06-11FilingAlembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper PublicationCompliance
- 2026-06-11FilingAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 11, 2026, titledPress Release
- 2026-06-09FilingAlembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper PublicationCompliance
- 2025-07-29ActionDividend - Rs 11 Per ShareDividend
- 2024-07-15ActionDividend - Rs 11 Per ShareDividend
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2Press ReleaseNeutral
a press release dated Jun 12, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Tretinoin Cream USP, 0.05%.".
Source PDF → - 2
- 1
- 2Press ReleaseNeutral
a press release dated Jun 11, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg".
Source PDF → - 1
No bulk/block deals for APLLTD in this window.
News & chatter on APLLTD
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.